🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced today

Find Clinical Trials for Your Rare Disease

12219+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Showing 20 of 12219 recruiting trials

Phase 2RecruitingNCT06434610

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

🏥 Shanghai Jiaolian Drug Research and Development Co., Ltd📍 17 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT05866562

Dupilumab in the Treatment of Pediatric Alopecia Areata

👨‍⚕️ Emma Guttman-Yassky, MD, PhD, Icahn School of Medicine at Mount Sinai📍 5 sites📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06340685

Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency

👨‍⚕️ Jirair Bedoyan, MD, PhD, UPMC Children's Hospital of Pittsburgh📍 1 site📅 Started Jul 2024View details ↗
Phase 2Enrolling by InvitationNCT06250777

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

👨‍⚕️ Hye Ryun Kim, Yonsei University Health system, Severance Hospital📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06264700

Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness

👨‍⚕️ Susan Creary, MD, MSc, Nationwide Children's Hospital📍 3 sites📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06500819

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

👨‍⚕️ Sneha Ramakrishna, MD, Stanford University📍 1 site📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06482190

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers

🏥 Shenzhen Resproly Biopharmaceutical Co., Ltd📍 3 sites📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT06287229

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

👨‍⚕️ Elias Jabbour, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Jul 2024View details ↗
Phase 4RecruitingNCT06538480

Zopa Retreatment and Vector Shedding in Adults With RRP

👨‍⚕️ Amy Lankford, PhD, Precigen, Inc📍 3 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06601309

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

🏥 Fujian Medical University Union Hospital📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06362733

Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth

👨‍⚕️ Antonio Hardan, MD, Stanford University📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06513234

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06420167

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

👨‍⚕️ Jeffrey Zonder, M.D., Barbara Ann Karmanos Cancer Institute📍 1 site📅 Started Jul 2024View details ↗
Phase 3RecruitingNCT06315322

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

🏥 UCB Biopharma SRL📍 23 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT05907759

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

👨‍⚕️ Robert Yarchoan, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT06213636

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

🏥 Essen Biotech📍 1 site📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06515613

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

👨‍⚕️ Karen Chagin, MD, Context Therapeutics Inc.📍 13 sites📅 Started Jul 2024View details ↗
RecruitingNCT06683690

TGF β 1 Expression Related Gene Polymorphism

👨‍⚕️ Moustafa Adam Ali El Taieb, Professor, Dermatology, Venereology and Andrology. Faculty of Medicine, Aswan University📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT06420076

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

🏥 Essen Biotech📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06050252

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

👨‍⚕️ Hop S Tran Cao, University of Texas MD Anderson Cancer Center LAO📍 58 sites📅 Started Jul 2024View details ↗
← PreviousPage 270 of 611Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →